These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 20055123)

  • 1. [Overseas Drug Safety Information 2008. Risk of infectious diseases associated with the use of immunosuppressive drugs].
    Amanuma K; Morikawa K
    Jpn J Antibiot; 2009 Oct; 62(5):460-70. PubMed ID: 20055123
    [No Abstract]   [Full Text] [Related]  

  • 2. How to evaluate the benefit-risk profile of newly marketed drugs.
    Naldi L
    Ann Dermatol Venereol; 2010 Apr; 137(4):264-6, 261-3. PubMed ID: 20417357
    [No Abstract]   [Full Text] [Related]  

  • 3. [A chance we take...].
    Paley-Vincent C
    Ann Dermatol Venereol; 2010 Apr; 137(4):257-9. PubMed ID: 20417355
    [No Abstract]   [Full Text] [Related]  

  • 4. Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: a cautionary tale for dermatologists.
    Korman BD; Tyler KL; Korman NJ
    Arch Dermatol; 2009 Aug; 145(8):937-42. PubMed ID: 19687432
    [No Abstract]   [Full Text] [Related]  

  • 5. Progressive multifocal leukoencephalopathy and antipsoriatic drugs: assessing the risk of immunosuppressive treatments.
    Di Lernia V
    Int J Dermatol; 2010 Jun; 49(6):631-5. PubMed ID: 20618466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurological complications of infliximab.
    Roos JC; Ostor AJ
    J Rheumatol; 2007 Jan; 34(1):236-7; author reply 237-8. PubMed ID: 17216699
    [No Abstract]   [Full Text] [Related]  

  • 7. [Splendours and miseries of the benefit-risk ratio].
    Dupuy A
    Ann Dermatol Venereol; 2010 Apr; 137(4):267-8. PubMed ID: 20417358
    [No Abstract]   [Full Text] [Related]  

  • 8. JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy?
    Verbeeck J; Van Assche G; Ryding J; Wollants E; Rans K; Vermeire S; Pourkarim MR; Noman M; Dillner J; Van Ranst M; Rutgeerts P
    Gut; 2008 Oct; 57(10):1393-7. PubMed ID: 18436577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progressive multifocal leukoencephalopathy developed 26 years after renal transplantation.
    Nagayama S; Gondo Y; Araya S; Minato N; Fujita-Nakata M; Kaito M; Nakanishi M; Tanaka K; Yamaya H; Yokoyama H; Nakamichi K; Saijo M; Okamoto K; Toyoshima Y; Kakita A; Matsui M
    Clin Neurol Neurosurg; 2013 Aug; 115(8):1482-4. PubMed ID: 23253820
    [No Abstract]   [Full Text] [Related]  

  • 10. Fingolimod-induced remission in a patient with ulcerative colitis and multiple sclerosis.
    Ladrón Abia P; Alcalá Vicente C; Martínez Delgado S; Bastida Paz G
    Gastroenterol Hepatol; 2021 Feb; 44(2):156-157. PubMed ID: 33199131
    [No Abstract]   [Full Text] [Related]  

  • 11. Anti-tumor necrosis factor alpha therapy and the risk of JC virus infection.
    Roos JC; Ostor AJ
    Arthritis Rheum; 2006 Jan; 54(1):381-2. PubMed ID: 16385537
    [No Abstract]   [Full Text] [Related]  

  • 12. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk?
    Molloy ES; Calabrese LH
    Autoimmun Rev; 2008 Dec; 8(2):144-6. PubMed ID: 18700172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does the flap of a butterfly's wings in Brazil set off a tornado in Texas?--The JC Virus Story in multiple sclerosis.
    Achiron A; Miron S; Shoenfeld Y
    Isr Med Assoc J; 2005 May; 7(5):283-5. PubMed ID: 15909458
    [No Abstract]   [Full Text] [Related]  

  • 14. Natalizumab: bound to rebound?
    Schiess N; Calabresi PA
    Neurology; 2009 Feb; 72(5):392-3. PubMed ID: 19188569
    [No Abstract]   [Full Text] [Related]  

  • 15. Progressive multifocal leukoencephalopathy: report of three cases in HIV-negative hematological patients and review of literature.
    Pelosini M; Focosi D; Rita F; Galimberti S; Caracciolo F; Benedetti E; Papineschi F; Petrini M
    Ann Hematol; 2008 May; 87(5):405-12. PubMed ID: 18064459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies.
    Molloy ES; Calabrese LH
    Arthritis Rheum; 2012 Sep; 64(9):3043-51. PubMed ID: 22422012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disproportionality signal of progressive multifocal leukoencephalopathy: monoclonal antibodies versus other immunosuppressants.
    Piccinni C; Sacripanti C; Poluzzi E; De Ponti F
    Pharmacoepidemiol Drug Saf; 2013 Apr; 22(4):443-5. PubMed ID: 23554080
    [No Abstract]   [Full Text] [Related]  

  • 18. Progressive multifocal leukoencephalopathy in liver transplant recipients: a case report and review of the literature.
    Verhelst X; Vanhooren G; Vanopdenbosch L; Casselman J; Laleman W; Pirenne J; Nevens F; Orlent H
    Transpl Int; 2011 Apr; 24(4):e30-4. PubMed ID: 21134241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progressive multifocal leukoencephalopathy after orthotopic liver transplantation.
    Worthmann F; Türker T; Müller AR; Patt S; Stoltenburg-Didinger G
    Transplantation; 1994 Apr; 57(8):1268-71. PubMed ID: 8178356
    [No Abstract]   [Full Text] [Related]  

  • 20. Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis.
    Schröder A; Lee DH; Hellwig K; Lukas C; Linker RA; Gold R
    Arch Neurol; 2010 Nov; 67(11):1391-4. PubMed ID: 20625069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.